Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $(0.21) by 244.19 percent. This is a 1133.33 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $30.615 million which beat the analyst consensus estimate of $28.875 million by 6.03 percent. This is a 0.04 percent increase over sales of $30.602 million the same period last year.